Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
|Recent News||More >>|
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Primary IR Contact|
|Scott T. Smith|
Chief Financial Officer
Data provided by Nasdaq. Minimum 15 minutes delayed.